10.80USD-4.01%Mkt Cap: 935.68M USDP/E: —Last update: 2026-05-26
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral sma…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap935.68M USD
Enterprise Value431.51M USD
Revenue (TTM)71.64M USD
Gross Profit67.42M USD
Net Income (TTM)-278.67M USD
Revenue/Share0.8140 USD
Last Price10.80 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees260
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.36
PEG—
EV/EBITDA-1.36
EV/Revenue6.02
P/S13.79
P/B9.16
EPS (TTM)-3.35
EPS (Forward)-2.55
52W Range
5.45076% of range12.49
52W High12.49 USD
52W Low5.450 USD
Profitability
Gross Margin99.92%
Oper. Margin-431.51%
EBITDA Margin0.00%
Profit Margin-412.95%
ROE-160.03%
ROA-37.74%
Growth
Revenue Growth29.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.06M USD
CapEx (TTM)6.64M USD
FCF Margin-181.23%
FCF Yield-13.88%
Net Debt-556.55M USD
Net Debt/EBITDA1.76
Balance Sheet
Debt/Equity0.12
Current Ratio6.15
Quick Ratio5.86
Book Value/Sh1.215 USD
Cash/Share6.543 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)31.17 USD
Target Range15.00 USD – 76.00 USD
# Analysts12
Ownership
Shares Out.88.77M
Float70.39M
Insiders1.44%
Institutions96.38%
Short Interest
Short Ratio11.3d
Short % Float17.85%
Short % Out.17.38%
Shares Short15.43M
Short (prev mo.)14.20M
Technical
SMA 508.971 (+20.4%)
SMA 2009.141 (+18.1%)
Beta0.32
S&P 52W Chg28.31%
Avg Vol (30d)1.66M
Avg Vol (10d)2.30M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—